ArticleClinical oral investigations2026
The effect of the injectable platelet-rich fibrin on peri-implant soft tissue phenotype: a preliminary, prospective, 12-month follow-up clinical study.
Article in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07667855 (Peri-implant Soft Tissue Augmentation Using Microneedling With i-PRF vs. Connective Tissue Graft), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peri-implant Soft Tissue Augmentation Using Microneedling With i-PRF vs. Connective Tissue Graft: A Randomized Controlled Clinical Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to assess the effectiveness of submucosal injectable platelet-rich fibrin(i-PRF) application on the peri-implant soft tissue phenotype and pink esthetic outcomes in thin and thick phenotypes. MATERIALS AND
methodsThe present study comprised 36 implants from 10 patients. Based on the probe visibility method, implants were classified into Group I (thin phenotype) or Group II (thick phenotype). i-PRF applications were performed three times at one-month intervals into the peri-implant keratinized submucosal and mucogingival junction region. Keratinized mucosal width (KMW), mucosal thickness (MT), and marginal soft tissue recession height (REC-H) and width (REC-W) were measured at baseline (T0), 1 (T1), 3(T3), 6 (T6), and 12 months (T12). Modified plaque index (mPI), modified gingival index (mGI), probing depth (PD), and pink esthetic score (PES) were recorded at T0 and T12. Statistical analyses were conducted utilizing Generalized Estimating Equations (GEE) in conjunction with Type III Wald Chi-square tests.
resultsIntragroup evaluations revealed that PD increased significantly between T0 and T12 in Group I (p = 0.02). Intra-group and inter-group post hoc analyses demonstrated that Group I exhibited statistically significant alterations in MT at all evaluated time points, with the exception of the interval between T6 and T12 (p < 0.05). In contrast, no statistically significant changes were observed in either MT or KTW in Group II (p > 0.05). Furthermore, significant intergroup differences in MT were identified at T0, T1, and T3 (p < 0.001, p < 0.001, and p = 0.005, respectively). Evaluation of the PES across all implants revealed statistically significant enhancements in the total PES, as well as in the soft-tissue colour and contour subcomponents (p = 0.00, p = 0.04, and p = 0.04, respectively).
conclusionsMultiple applications of peri-implant i-PRF may alter the mucosal phenotype, particularly in thin phenotype cases, and consequently may lead to changes in the pink aesthetic score. Further research with larger samples is required. CLINICAL RELEVANCE: Multiple i-PRF injections applied to peri-implant sites may modify the particularly thin phenotype and may offer a new approach for clinical applications in limited cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.